Literature DB >> 14178031

SENSITIVITY TO HISTOPLASMIN AMONG NEGRO AND WHITE RESIDENTS OF DIFFERENT COMMUNITIES IN THE USA.

P Q EDWARDS, C E PALMER.   

Abstract

The frequency of infection with the fungus Histoplasma, as judged by the results of skin tests with histoplasmin, varies widely from county to county across the USA and even over very short distances within some counties. Differences between various segments of the population, such as between Negroes and whites, living in one particular community are therefore difficult to interpret, as they might represent the effect of differences in ecological rather than in demographic factors within the community. Since the pertinent ecological differences could, however, be expected to balance out if a large number of communities were sampled, results of histoplasmin skin tests among Negro and white Navy recruits from 37 different communities are compared in the present report. The prevalence of reactors to histoplasmin ranges from zero to over 90% in residents of the different geographical areas, indicating wide variations in the ecological conditions affecting the growth and dissemination of the fungus, yet comparisons of results in Negroes and whites indicate that the factors influencing infection and sensitization of man appear to bear equally on both racial groups. Results with tuberculin PPD-S and the Battey PPD antigen in the same groups of recruits are included to supplement the results with histoplasmin.

Entities:  

Keywords:  CAUCASIAN RACE; HISTOPLASMIN; HISTOPLASMOSIS; NEGROES; SKIN TESTS; STATISTICS; TUBERCULIN TEST; UNITED STATES

Mesh:

Substances:

Year:  1964        PMID: 14178031      PMCID: PMC2554837     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Geographic variation in the prevalence of histoplasmin sensitivity in the Panama Canal Zone.

Authors:  R L TAYLOR
Journal:  Am J Trop Med Hyg       Date:  1962-09       Impact factor: 2.345

2.  Tests of immunity in histoplasmosis.

Authors:  M L FURCOLOW
Journal:  N Engl J Med       Date:  1963-02-14       Impact factor: 91.245

3.  Epidemiological evidence of the presence of non-tuberculous sensitivity to tuberculin in Queensland.

Authors:  E W ABRAHAMS; H SILVERSTONE
Journal:  Tubercle       Date:  1961-12

4.  Epidemiologic studies of tuberculin sensitivity. III. Estimation of prevalences of myobacterial infection from results of skin tests with mycobacterial antigens.

Authors:  S NISSEN-MEYER
Journal:  Am J Hyg       Date:  1960-09

5.  An urban focus of histoplasmin sensitivity.

Authors:  D L ARONSON; P Q EDWARDS
Journal:  Am Rev Tuberc       Date:  1959-01

6.  Epidemiologic studies of tuberculin sensitivity. II. Response to experimental infection with myobacteria isolated from human sources.

Authors:  L B EDWARDS; C E PALMER; L F AFFRONTI; L HOPWOOD; P Q EDWARDS
Journal:  Am J Hyg       Date:  1960-03

7.  Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity.

Authors:  C E PALMER; L B EDWARDS; L HOPWOOD; P Q EDWARDS
Journal:  J Pediatr       Date:  1959-10       Impact factor: 4.406

8.  The Walworth, Wisconsin, epidemic of histoplasmosis.

Authors:  K R WILCOX; B A WAISBREN; J MARTIN
Journal:  Ann Intern Med       Date:  1958-08       Impact factor: 25.391

9.  Nationwide histoplasmin sensitivity and histoplasmal infection.

Authors:  Phyllis Q Edwards; Carroll E Palmer
Journal:  Public Health Rep       Date:  1963-03       Impact factor: 2.792

10.  Sensitivity to avian and human old tuberculin in man in Great Britain.

Authors:  P D HART; C L MILLER; I SUTHERLAND; I W LESSLIE
Journal:  Tubercle       Date:  1962-09
View more
  2 in total

1.  Correlation of tuberculin sensitivity before and after BCG vaccination.

Authors:  J Guld
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

2.  Racial inequality in the annual risk of Tuberculosis infection in the United States, 1910-1933.

Authors:  J L Zelner; C Muller; J J Feigenbaum
Journal:  Epidemiol Infect       Date:  2017-04-24       Impact factor: 4.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.